Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures

AAPS Journal

Volumn 12, Issue 2, 2010, Pages 215-222

  Geeraedts, Felix ^a   Saluja, Vinay ^b   Ter Veer, Wouter ^a   Amorij, Jean Pierre ^b,c   Frijlink, Henderik W ^b   Wilschut, Jan ^a   Hinrichs, Wouter L J ^b   Huckriede, Anke ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c NETHERLANDS VACCINE INSTITUTE   (Netherlands)

Author keywords

Freeze drying; Inulin; Pandemic influenza; Vaccine stockpiling; Whole inactivated influenza vaccine (H5N1)

Indexed keywords

INFLUENZA H5N1 WHOLE INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INULIN; STABILIZING AGENT; TREHALOSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG STABILITY; DRY POWDER; ENVIRONMENTAL TEMPERATURE; FEMALE; FREEZE DRYING; HEMOLYSIS; HIGH TEMPERATURE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; SHELF LIFE; STORAGE TEMPERATURE; TH1 CELL; VIRUS HEMAGGLUTINATION; VIRUS PARTICLE;

ANIMALS; DESICCATION; DRUG STABILITY; DRUG STORAGE; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTES; EXCIPIENTS; FEMALE; FREEZE DRYING; HEMAGGLUTINATION TESTS; HEMOLYSIS; IMMUNIZATION; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INULIN; MICE; MICE, INBRED BALB C; POWDERS; TEMPERATURE; TREHALOSE; VACCINES, INACTIVATED;

EID: 77950681753     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9179-z     Document Type: Article

References (58)

1. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med. 2002;76:105-115
2. World Health Organization http://www.who.int/mediacentre/news/statements/ 2009/h1n1-pandemic-phase6-20090611/en/index.html.
3. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360:2605-2615
4. Update: novel influenza A (H1N1) virus infections-worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:453-458
5. Fraser C, Donnelly CA, Cauchemez S, HanageWP, Van Kerkhove MD, Hollingsworth TD, et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science. 2009;324:1557-1561
6. World Health Organization http://www.who.int/csr/don/2009-06-12/en/index. html.
7. Nguyen-Van-Tam JS, Hampson AW. The epidemiology and clinical impact of pandemic influenza. Vaccine. 2003;21:1762-1768
8. FedsonDS. Vaccine development for an imminent pandemic: why we should worry, what we must do. Hum Vaccin. 2006;2:38-42.
9. Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG. Characterization of the 1918 influenza virus polymerase genes. Nature. 2005;437:889-893 (Pubitemid 41486764)
10. World Health Organization http://www.who.int/csr/disease/avian-influenza/ country/cases-table-2009-06-02/en/index.html.
11. World Health Organization http://www.who.int/csr/resources/publications/ influenza/WHO-CDS-CSR-GIP-2005-5/en/.
12. Uscher-Pines L, Omer SB, Barnett DJ, Burke TA, Balicer RD. Priority setting for pandemic influenza: an analysis of national preparedness plans. PLoS Med. 2006;3:e436.
13. Monto AS. Vaccines and antiviral drugs in pandemic preparedness. Emerg Infect Dis. 2006;12:55-60.
14. Hayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis. 2006;194 Suppl 2:S119-26. (Pubitemid 44630955)
15. Longini Jr IM, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DA, et al. Containing pandemic influenza at the source. Science. 2005;309:1083-1087 (Pubitemid 41134467)
16. Ehrlich HJ, Muller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med. 2008;358:2573-2584 (Pubitemid 351831358)
17. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007;370:580-589 (Pubitemid 47247854)
18. Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis. 2008;198:642-649
19. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet. 2006;368:991-997 (Pubitemid 44353667)
20. Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, Pistoor FH, et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One. 2008;3:e1401. (Pubitemid 351194015)
21. Fazekas G, Martosne-Mendi R, Jankovics I, Szilvasy I, Vajo Z. Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains. Clin Vaccine Immunol. 2009;16:437-443
22. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis. 2006;194:159-167 (Pubitemid 44087186)
23. Murakami S, Iwasa A, Iwatsuki-Horimoto K, Ito M, Kiso M, Kida H, et al. Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model. Vaccine. 2008;26:6398-6404
24. Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, Meeyai A, et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature. 2005;437:209-214 (Pubitemid 41294478)
25. Riley S, Wu JT, Leung GM. Optimizing the dose of prepandemic influenza vaccines to reduce the infection attack rate. PLoS Med. 2007;4:e218.
26. Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis. 2008;198:635-641
27. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis. 2008;8:650-658
28. Coenen F, Tolboom JT, Frijlink HW. Stability of influenza subunit vaccine. Does a couple of days outside the refrigerator matter? Vaccine. 2006;24:525-531
29. Huang J, Garmise RJ, Crowder TM, Mar K, Hwang CR, Hickey AJ, et al. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine. 2004;23:794-801. (Pubitemid 39473178)
30. Schoub BD, Cameron NA. Problems encountered in the delivery and storage of OPV in an African country. Dev Biol Stand. 1996;87:27-32.
31. Amorij JP, Huckriede A, Wilschut J, Frijlink HW, Hinrichs WL. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res. 2008;25:1256-1273
32. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203:1-60. (Pubitemid 30627625)
33. Amorij JP, Meulenaar J, Hinrichs WL, Stegmann T, Huckriede A, Coenen F, et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine. 2007;25:6447-6457 (Pubitemid 47198923)
34. Maa YF, Ameri M, Shu C, Payne LG, Chen D. Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation. J Pharm Sci. 2004;93:1912-1923 (Pubitemid 38823716)
35. Crowe LM, Crowe JH, Rudolph A, Womersley C, Appel L. Preservation of freeze-dried liposomes by trehalose. Arch Biochem Biophys. 1985;242:240-247 (Pubitemid 16224092)
36. Vereyken IJ, Chupin V, Hoekstra FA, Smeekens SC, de Kruijff B. The effect of fructan on membrane lipid organization and dynamics in the dry state. Biophys J. 2003;84:3759-3766 (Pubitemid 36637871)
37. Williams MS, Mayner RE, Daniel NJ, Phelan MA, Rastogi SC, Bozeman FM, et al. New developments in the measurement of the hemagglutinin content of influenza virus vaccines by singleradial-immunodiffusion. J Biol Stand. 1980;8:289-296
38. de Jonge J, Amorij JP, Hinrichs WL, Wilschut J, Huckriede A, Frijlink HW. Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. Eur J Pharm Sci. 2007;32:33-44. (Pubitemid 47102189)
39. Hinrichs WL, Prinsen MG, Frijlink HW. Inulin glasses for the stabilization of therapeutic proteins. Int J Pharm. 2001;215:163-744
40. Stegmann T, Morselt HW, Booy FP, van Breemen JF, Scherphof G, Wilschut J. Functional reconstitution of influenza virus envelopes. EMBO J. 1987;6:2651-2659
41. Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog. 2008;4:e1000138.
42. Geeraedts F, Bungener L, Pool J, ter Veer W, Wilschut J, Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respi Viruses. 2008;2:41-51.
43. Hovden AO, Cox RJ, Haaheim LR. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand J Immunol. 2005;62:36-44.
44. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine. 2008;26:2350-2359
45. Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, et al. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine. 2008;26:6555-63.
46. World Health Organization http://www.who.int/vaccines-documents/ DocsPDF06/863.pdf.
47. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303:1529-1531 (Pubitemid 38314425)
48. Garmise RJ, Staats HF, Hickey AJ. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS PharmSciTech. 2007;8:E81.
49. Levy JA, Fieldsteel AH. Freeze-drying is an effective method for preserving infectious type C retroviruses. J Virol Methods. 1982;5:165-171
50. Yannarell DA, Goldberg KM, Hjorth RN. Stabilizing coldadapted influenza virus vaccine under various storage conditions. J Virol Methods. 2002;102:15-25.
51. Hincha DK, Zuther E, Hellwege EM, Heyer AG. Specific effects of fructo- and gluco-oligosaccharides in the preservation of liposomes during drying. Glycobiology. 2002;12:103-110 (Pubitemid 34428933)
52. ICH Harmonised Tripartite Guideline http://www.ich.org/LOB/media/ MEDIA419.pdf
53. Koyama S, Ishii KJ, Kumar H, Tanimoto T, Coban C, Uematsu S, et al. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J Immunol. 2007;179:4711-4720
54. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70:767-777
55. P.M. Kendal AP, Skehel J. Concepts and procedures for laboratory-based influenza surveillance. Centers for Disease Control, Atlanta, GA. Publication No. B17-35. (1982).
56. Hovden AO, Cox RJ, Madhun A, Haaheim LR. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scand J Immunol. 2005;62:342-352 (Pubitemid 41565386)
57. Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol. 2006;13:981-990 (Pubitemid 44518965)
58. Krause PR. Goals of stability evaluation throughout the vaccine life cycle. Biologicals. 2009;37:369-78. discussion 421-423